In an era where immunotherapeutic agents now provide durable efficacy and improved outcomes for patients with metastatic melanoma, a thorough understanding of the FcγRIIB pathway and its T cell–autonomous inhibitory role in melanoma-specific immunity will contribute to further improvement in pharmacologic strategies and patient outcomes. This evidence concerns the gene FCGR2B and melanoma.